Giuliano S. Borges
Tapirama, BA, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Treatment of ALK+ Non-Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918).
Journal: JCO global oncology
Published: June 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 17, 2026
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia.
Journal: The New England journal of medicine
Published: March 11, 2026
Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response.
Journal: Clinical breast cancer
Published: February 26, 2026
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 30, 2025
Determinants of delayed postoperative radiation therapy in breast cancer patients undergoing neoadjuvant chemotherapy: A subanalysis of the AMAZONA III prospective cohort.
Journal: Cancer treatment and research communications
Published: May 05, 2025
Germline Genetic Testing in Breast Cancer: Utilization and Disparities in a Middle-Income Country.
Journal: JCO global oncology
Published: March 07, 2025
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Journal: Gynecologic oncology
Published: December 23, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 12, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Journal: Nature medicine
Published: March 29, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Journal: Lancet (London, England)
Published: March 14, 2023
Last Updated: 09/26/2026